Which is better, GMAB or PCVX?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than PCVX — 65/100 (C grade) vs 15/100 (F). That said, "better" depends on which framework you trust — GMAB wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; PCVX wins on none. The full pillar breakdown is on this page.

Should I buy GMAB or PCVX?

This page is an educational comparison, not investment advice. Both GMAB and PCVX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GMAB better than PCVX for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 15/100, a 50-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between GMAB and PCVX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GMAB currently scores 65/100 (C grade); PCVX scores 15/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GMAB or PCVX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GMAB and PCVX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GMAB or PCVX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GMAB and PCVX both Healthcare stocks?

Yes — both Genmab A/S (GMAB) and Vaxcyte, Inc. (PCVX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GMAB vs PCVX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Genmab A/S

Vaxcyte

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

PCVX

Vaxcyte

Market cap

$6.83B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	GMAB	PCVX	Winner
Warren Buffett	65C	15F	GMAB
Benjamin Graham	64C	46D	GMAB
Philip Fisher	48D	36D	GMAB
Peter Lynch	25F	11F	GMAB
Joel Greenblatt	76B	0F	GMAB
Charlie Munger	68C	25F	GMAB
Terry Smith	71C	30F	GMAB

Side-by-side metrics

Metric	GMAB	PCVX
Market cap	$16.5B	$6.83B
P/E (TTM)	6.2x	-
EV/EBIT	12.0x	-
ROIC (TTM)	43.78%	-34.98%
Gross margin	93.88%	0.0%
Net margin	18.23%	0.0%
Revenue CAGR 5y	-18.45%	-
EPS CAGR 5y	-23.48%	-
Debt / Equity	0.1x	0.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMAB leads on

ROIC (TTM)43.78%vs -34.98%+180%
Gross margin93.88%vs 0.0%+100%
Net margin18.23%vs 0.0%+100%
Market cap$16.5Bvs $6.83B+59%

PCVX leads on

P/E (TTM)-vs 6.2x+180%
EV/EBIT-vs 12.0x+167%
Debt / Equity0.0xvs 0.1x+47%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Genmab A/S

Vaxcyte

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like GMAB

More like PCVX

Related on invest-like

Key terms in this analysis